Multicentre study examines hospitalization risks and disease burden in acute intermittent porphyria, indicating need for better management.
In this multicentre European study, we describe disease burden across all clinical AIP states including non-givosiran treated recurrent patients and identify risk factors associated with hospitalization and recurrent disease.
No takes yet. Share an insight, caveat, or question.
Baravelli et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: